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ABSTRACT
Mutations in the mismatch repair (MMR) genes
MSH2, MSH6, MLH1 and PMS2 are associated with
Lynch Syndrome (LS), a familial predisposition to
early-onset cancer of the colon and other organs.
Because not all LS families carry mutations in these
four genes, the search for cancer-associated muta-
tions was extended to genes encoding other mem-
bers of the mismatch repairosome. This effort iden-
tified mutations in EXO1, which encodes the sole ex-
onuclease implicated in MMR. One of these muta-
tions, E109K, was reported to abrogate the catalytic
activity of the enzyme, yet, in the crystal structure of
the EXO1/DNA complex, this glutamate is far away
from both DNA and the catalytic site of the enzyme.
In an attempt to elucidate the reason underlying the
putative loss of function of this variant, we expressed
it in Escherichia coli, and tested its activity in a series
of biochemical assays. We now report that, contrary
to earlier reports, and unlike the catalytic site mutant
D173A, the EXO1 E109K variant resembled the wild-
type (wt) enzyme on all tested substrates. In the light
of our findings, we attempt here to reinterpret the re-
sults of the phenotypic characterization of a knock-in
mouse carrying the E109K mutation and cells derived
from it.
INTRODUCTION
Postreplicative mismatch repair (MMR) improves replica-
tion fidelity by two to three orders of magnitude and is thus
one of the key guardians of genomic stability in replicating
cells (1,2). The clinical importance of MMR is clearly ap-
parent from its association with Lynch Syndrome (LS, also
known as hereditary non-polyposis colon cancer, HNPCC),
in which inheritance of mutated alleles ofMMR genes pre-
disposes to cancer of the colon, endometrium and other or-
gans (3). The majority of MMR gene mutations affect the
MLH1 andMSH2 loci, but families carrying mutations in
MSH6 and PMS2 have also been identified. However, as
these fail to account for all known LS kindreds, attention
was focused on other genes that encodeMMRproteins, and
this effort culminated in the identification of mutations in
EXO1 (4). This gene encodes amember of the evolutionarily
highly conserved RAD2 family of structure-specific nucle-
ases, first discovered in Schizosaccharomyces pombe, where
it was shown to play a role in meiotic recombination (5)
and later also in MMR (6). Since then, EXO1 has been the
subject of numerous genetic and biochemical studies, pre-
dominantly in Saccharomyces cerevisiae, but also in mouse
and human cells. These findings implicated the enzyme in
several additional processes of DNAmetabolism, including
replication, mitotic recombination, double strand break re-
pair, antibody diversification and telomeremaintenance [for
reviews, see (7,8)].
Yeast two-hybrid assays and biochemical pull-down ex-
periments showed that EXO1 can interact with MLH1
and MSH2 (9–13), as well as with Proliferating Cell Nu-
clear Antigen (PCNA) (14,15), all major players in MMR.
Implication of the S. cerevisiae enzyme in MMR in vivo
proved to be more challenging, given that the mutator phe-
notype of EXO1-deficient cells was substantially weaker
than that of MSH2- or MLH1-disrupted strains. The nu-
clease activity of the enzyme was shown to be required
for suppression of the conditional viability of a MSH2-
deficient S. cerevisiae strain expressing a proofreading-
deficient polymerase- (16), but it was only through the
use of hypomorphic S. cerevisiae MMR alleles that EXO1
could be shown to be epistatic with other MMR genes
(13,17,18). Subsequent studies indicated that full function-
ality of EXO1 in MMR requires both the nuclease and
the MLH1-interacting domains (12,19), and data obtained
with the human system reconstituted from purified recom-
binant proteins, which demonstrated that the activity of
EXO1 during MMR is controlled by interaction with the
MSH2/MSH6 (MutS) and MLH1/PMS2 (MutL) het-
erodimers (20,21), provided additional evidence suggesting
that the protein plays a catalytic as well as a structural role
in the processing of biosynthetic errors.
The modest mutability associated with EXO1 deficiency
in both yeast (12,22) and mice (23), explained by the ex-
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istence of redundant nucleases, as well as by the exis-
tence of an EXO1-independent, but MLH1/PMS2- and
polymerase--dependent strand displacement mechanism
of mismatch correction (24), led to the expectation that mu-
tations in EXO1 in LS families are likely to be rare and
linked to late cancer onset and low penetrance. Germline
mutations in EXO1 were indeed identified, but their link to
cancer was less than convincing. Thus, in the first study,
the tumours were reported to have lost preferentially the
mutant- rather than the wild-type allele, and some displayed
microsatellite instability (MSI) at both mono- and dinu-
cleotide markers, a phenotype characteristic of full MMR
defect, which differs from findings in EXO1-deficient yeast
(12,22) and mice (23), where only a subset of mononu-
cleotide runs was unstable. A follow-up study reported
that the identified mutations often affected non-conserved
residues and were observed with similar frequencies also in
controls (25). Most importantly, two families affected with
multiple cutaneous and uterine leiomyomatosis, carrying
germline deletions on chromosome 1 that included EXO1,
displayed no predisposition to colon cancer and their tu-
mours displayed no MSI (26). Surprisingly, although the
above findings suggested that EXO1mutations are not can-
cer predisposing, biochemical defects were described for
eight of the reported EXO1 variants (27).
We became interested in the E109K mutant, which was
found to be enzymatically inactive, even though the amino
acid change did not affect the catalytic site. Moreover,
recently described knock-in mice harbouring the EXO1
E109K mutation and cells derived from these animals (28)
displayed phenotypic traits [e.g. wild-type-like mutation
rates and frequency of somatic hypermutation and class
switch recombination, yet elevated resistance to the SN1
methylating agent N-methyl-N′-nitro-N-nitrosoguanidine
(MNNG)] that were incompatible with our current under-
standing of the role of this enzyme inDNAmetabolism.We,
therefore, expressed theEXO1E109Kvariant inEscherichia
coli and studied its biochemical properties in an attempt to
learn how this mutation affects its enzymology.
MATERIALS AND METHODS
EXO1 expression and purification
The pTXB1 vector (IMPACTTM Kit, NEB) encoding the
wild-type EXO1 cDNA and the D173A mutant, both
with a C-terminal intein tag, were kindly provided by
Stefano Ferrari. The E109K mutation was introduced
using the following primers: 5′-CTTAAGGGAAAG
CAACTTCTTCGTAAGGGGAAAGTCTCGG-3′ and
5′-CCGAGACTTTCCCCTTACGAAGAAGTTGCT
TTCCCTTAAG-3′. The template was incubated in the
presence of these primers (30 M) in 1× Phusion buffer,
0.8 mM deoxynucleoside triphosphates (dNTPs) and 2 U
Phusion polymerase (NEB), subjected to polymerase chain
reaction (PCR) amplification (95◦C, 2 min, then 35 cycles
of 95◦C, 30 s; 55◦C, 1 min, 72◦C, 8 min; followed by a
final elongation step at 72◦C, 10 min) and the product was
digested with 40 U DpnI (NEB) for 1 h, 37◦C.
The plasmids were transformed into the E. coli strain
BL21 and grown to an OD600 of 0.3 in LB medium sup-
plemented with chloramphenicol (25g/ml) and ampicillin
(100 g/ml). 0.2 mM isopropylthiogalactoside (IPTG) was
added to induce protein expression overnight at 18◦C with
shaking at 250 rpm. Subsequently, the bacteria were har-
vested by centrifugation (4000 rpm, 10 min, 4◦C, Sor-
vall SLA-3000 rotor), washed with 1× phosphate buffered
saline (PBS) and snap-frozen. Bacterial pellets were sus-
pended in CH buffer (20 mM Tris pH 8.0, 500 mM
NaCl, 0.1% Triton X100, 1 mMEDTA (ethylenediaminete-
traacetic acid), 10% glycerol) and sonicated prior to load-
ing on chitin beads. The beads were then washed with CH
buffer and the proteolytic cleavage of the intein tag was in-
duced by incubation with CH buffer supplemented with 30
mM dithiothreitol (DTT) overnight at 4◦C. The slurry was
spun down (3220× g, 10min, 4◦C) and the supernatant was
clarified (20 000 × g, Eppendorf 5810R centrifuge, 45 min,
4◦C) and aliquotted in liquid nitrogen.
Non-specific endonuclease assay
Forty-eight femtomoles of a supercoiled plasmidDNA sub-
strate were incubated with 10 nM EXO1. The reaction was
carried out in a total volume of 20 l in 20 mM Tris·HCl
pH 7.6, 110 mMKCl, 5 mMMgCl2, 1 mM glutathione and
75 g/ml BSA (bovine serum albumin), for 30 min at 37◦C,
followed by heat inactivation (5 min, 80◦C). The nicking re-
action was carried out with 48 fmol of the substrate and 5
U Nt·BstNBI (NEB) in 100 mM NaCl, 50 mM Tris·HCl,
10 mM MgCl2 and 1 mM DTT for 30 min at 37◦C. Forty-
eight femtomoles of the substrate were incubated in 40 mM
Tris·HCl, 10 mMNaCl, 6 mMMgCl2, 1 mM CaCl2 with 3
U DNaseI (Roche) for 30 min at 37◦C. The reaction prod-
ucts were separated on a 1% agarose gel eluted with Tris
acetate EDTA (TAE) buffer and stained with GelRed. The
image was quantified with ImageQuantTL, and expressed
as a ratio of nicked versus total DNA.
Knock-down of EXO1
HEK293 cells were transfected with siRNA-EXO1 (5′-
CAAGCCUAUUCUCGUAUUUTT-3′; Microsynth) (7)
at 60% confluency, using a standard calcium phosphate pre-
cipitation protocol. The cells were harvested after 72 h, and
nuclear extracts were prepared as described in (29).
Mismatch repair assays
The in vitroMMR assays were carried out as described pre-
viously (29). Briefly, the heteroduplex phagemid DNA sub-
strate (48 fmol) containing a T/G mismatch in its unique
SalI site and a single nick generated by Nt·BstNBI 361 nu-
cleotides 5′ from the mispaired T was incubated with 100
g of nuclear extracts of HEK293 cells pretreated or not
with EXO1 siRNA and supplemented with 40 nMExo1 wt,
E109K or D173A in 20 mMTris·HCl pH 7.6, 110 mMKCl,
5 mM MgCl2, 1 mM glutathione, 1.5 mM ATP, 50 g/ml
BSA and 100 MdNTPs for 30 min in a total volume of 25
l. The reactions were terminated by a 30-min incubation
with a stop solution (final concentrations: 0.5 mM EDTA,
1.5% SDS (sodium dodecyl sulfate), 2.5 mg/ml proteinase
K), cleaned up on aMinElute column (Qiagen), and the re-
covered phagemid was subjected to restriction digest with
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6 U SalI and 20 U DraI (NEB). RNase A (40 ng, Sigma-
Aldrich) was then added and, following an overnight in-
cubation at 37◦C, the reaction products were separated on
a 1% agarose gel eluted with TAE buffer and stained with
GelRed.
Exonuclease assays
To measure enzyme processivity, supercoiled homoduplex
C/G DNA substrate (48 fmol) generated by primer exten-
sion on single-stranded phagemid template and purified on
a CsCl gradient (29) was nicked with Nt·BstNBI (NEB)
and incubated with the indicated amounts of EXO1 or its
variants in a total volume of 20 l in 20 mM Tris·HCl
pH 7.6, 110 mM KCl, 5 mM MgCl2, 1 mM glutathione
and 75 g/ml BSA, for the indicated times at 30◦C, fol-
lowed by heat inactivation (5min, 80◦C). The reaction prod-
ucts were separated on 1% agarose gels eluted with TAE
buffer and visualized with GelRed. The 5′ exonuclease ac-
tivity was measured using 100 fmol of a 5′-32P labelled 5′
recessed oligonucleotide 5′-GAGATATTCCTGGTCAGC
GTGACCGGAGCTGAAAG-3′ annealed with a 2-fold
excess of the unlabelled oligonucleotide 5′-CTTTCAGCTC
CGGTCACGCTGACCAGGAATATCTCTCTA-3′ (Mi-
crosynth) in a 10 l total volume under the above condi-
tions. The products were separated on 20%denaturing poly-
acrylamide gels, which were fixed, dried and exposed to
PhosphoImager screens. The images were quantified with
ImageJ (Fig. 4AB) or ImageQuantTL (Fig. 4C), whereby
the degraded DNA was plotted against the total amount of
DNA.
Endonuclease assays
To test the endonucleolytic activity of EXO1, we used a
splayed-arm substrate generated by annealing the 5′ 32P-
labelled oligonucleotide 5′-TCAAAGTCACGACCTAGA
CACTGCGAGCTCGAATTCACTGGAGTGACCTC-3′
with a 2-fold excess of the unlabelled oligonucleotide
5′-GAGGTCACTCCAGTGAATTCGAGCTCGCAG
CAATGAGCACATACCTAGT-3′ (Microsynth) in 1×
NEB buffer 2. The substrate (500 fmol) was incubated
with 5 nM EXO1 variants in a total volume of 50 l in 20
mM Tris·HCl pH 7.6, 110 mM KCl, 5 mM MgCl2, 1 mM
glutathione and 75 g/ml BSA at 30◦C and samples were
taken at the indicated time points. The reaction products
were isolated by ethanol precipitation, separated on 20%
denaturing polyacrylamide gels, analyzed by exposing the
dried gels to PhosphoImager screens and quantified with
ImageQuantTL.
Far-western analyses
This experiment was carried out as described (30) without
modification, using recombinant MutS (31) or CtIP (32).
The anti-Exo1 antibody was purchased from Neomarkers
(Ab-4), the anti-FLAG antibody was from Sigma (Anti-
FLAGM2 monoclonal antibody).
RESULTS
Exonuclease 1 belongs to the RAD2 family of structure-
specific endonucleases (33), the N-terminal and internal nu-
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Figure 1. Structure, expression and purification of wild-type EXO1 and
its E109K and D173A variants. (A) Structure of human EXO1 bound
to DNA [3QEB.pdb; (36)]. Catalytic metal ions are depicted as purple
spheres, the catalytic aspartate 173 is indicated in red and glutamate 109
in blue. (B) Recombinant EXO1 wild-type (wt), E109K (EK) and D173A
(DA) variant proteins used in this study. The figure is a scan of a 4–
15% SDS-polyacrylamide gel stained with Coomassie blue. M, pre-stained
molecular size marker. (C) EXO1 wild-type and its E109K and D173A
variants are devoid of non-specific endonucleolytic activity, as revealed by
their inability to convert supercoiled phagemid DNA into a nicked, open
circular form upon 30 min incubation with 10 nM variants. As a control,
the plasmid was digested with NtBstNBI, a nickase with a single recogni-
tion site in this vector, or with DNaseI. Single-stranded phagemid DNA
was included as a control.
clease domains of which are highly conserved from bac-
teriophage to man (33,34). EXO1 possesses 5′→3′ exonu-
clease and flap endonuclease activities (35) that share the
same active site, composed of twoMg2+ atoms coordinated
by five aspartate residues. In human EXO1, these are D30,
D152, D171, D173 and D225 (36). Glutamate 109 is not
part of the active site; it resides in a flexible loop between -
helices 4 and 5 (Figure 1A) that form, together with the
-sheet 3, a mobile microdomain, which was postulated
to mediate protein/protein interactions (36). As the E109K
mutation replaces a negatively charged residue with a pos-
itively charged one, we wanted to test whether it perturbs
intermolecular protein/protein interactions between EXO1
and its partners during MMR.
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Figure 2. Wild-type EXO1 and its E109K and D173A variants interact di-
rectly withMSH2 and CtIP. (A) Far-western blot showing a direct interac-
tion between EXO1 andMSH2. TheMSH2/MSH6 (MutS) heterodimer
was separated by SDS-PAGE (left panel) and the MSH6 and MSH2 sub-
units were transferred onto a membrane, which was subsequently incu-
bated with the recombinant EXO1 variants (right panels). Hybridization
with an anti-EXO1 antibody revealed specific interactions of the variants
with the MSH2 subunit of MutS. BSA was run on the SDS-PAGE gel
and used as a negative control for interaction with EXO1. M, pre-stained
molecular size marker. (B) Far-western blot showing a direct interaction
between EXO1 and CtIP. EXO1 wild-type and mutants were separated by
SDS-PAGE (Coomassie staining top panel), transferred onto a membrane
and incubated with recombinant FLAG-tagged CtIP. The interaction was
revealed upon hybridization of the membrane with anti-FLAG to detect
CtIP (bottom panel). M, pre-stained molecular size marker.
Using site-directed mutagenesis (see ‘Materials and
Methods’ section), we modified the bacterial expression
plasmid pTXB1 encoding the C-terminally intein-tagged
EXO1 to generate vectors encoding the variants E109K
(Supplementary Figure S1A) and D173A (Supplementary
Figure S1B), the latter of whichwas reported to be nuclease-
dead (18). We then expressed the tagged wild-type protein
and the twomutants inE. coliBL21 and isolated the recom-
binant polypeptides by chitin bead affinity chromatography,
during which the intein tag was cleaved off with DTT. As
shown in Figure 1B, the proteins were>85% homogeneous.
The preparations were free of contaminating unspecific en-
donucleases, as shown by the lack of nicking of supercoiled
phagemid DNA (Figure 1C).
We then asked whether the EXO1 variants interacted
with the MSH2 subunit of the mismatch recognition fac-
tor MutS as reported previously (6,9,10,22). We separated
the MSH6 and MSH2 subunits of purified recombinant
MutS on a denaturing polyacrylamide gel, electrotrans-
ferred the polypeptides onto a nitrocellulose membrane, de-
natured them in 6 M guanidinium hydrochloride, allowed
them to renature and then incubated them with the recom-
binant EXO1 variants. Following extensive washing, we vi-
sualized the bound EXO1 variants with an anti-EXO1 an-
tibody. BSA was used as the negative control. As shown
in Figure 2A, all three variants interacted efficiently with
MSH2 on these far-western blots.
EXO1 was also described to interact with CtIP, a
polypeptide involved in the resection of DNA double-
strand breaks (DSBs) (37). As mouse embryonic fibroblasts
expressing the E109K mutant were reported to be hyper-
sensitive to camptothecin (28), which induces DSBs during
replication, we wanted to test whether the interaction of this
variant with CtIP might be perturbed. However, as shown
by far-western blotting (Figure 2B), all three EXO1 vari-
ants behaved similarly in this assay. Both interactions were
highly selective, given that EXO1 failed to bind to BSA even
when used in large excess. Moreover, the fact that all vari-
ants interacted to similar extents with their target proteins
even after denaturation and renaturation indicated that the
mutations did not alter the stability of the polypeptides.
Rather than examine further individual interactions be-
tween EXO1 and purified MMR proteins MLH1 and
PCNA, which EXO1 has also been reported to bind
(11,13,15,19), we decided to test the functionality of the
EXO1 variants in an in vitro MMR assay, in which a
phagemid heteroduplex substrate carrying a single T/G
mismatch and a strand discrimination signal (a single nick
generated by Nt.BstNBI) 361 nucleotides 5′ from the mis-
paired T was incubated with extracts of human cells (29).
In this assay, the mismatch makes the phagemid refractory
to cleavage with SalI, but correction of the mismatch to
C/G through EXO1-mediated degradation of the nicked T-
strand and repair synthesis restores the restriction site (29).
SalI/DraI digestion of the repaired phagemid recovered
from the extract thus gives rise to four fragments of 1324,
1160, 694 and 19 bp, whereas the uncorrected phagemid is
cleaved only by DraI into fragments of 2484, 694 and 19 bp
(Figure 3A).
When the nicked T/G phagemid was incubated with
HEK293 nuclear extracts (Figure 3B, lane 1), ∼60% of the
substrate were corrected to C/G as indicated by the rela-
tive intensity of the 1324 and 1160 bp bands. In contrast,
incubation of the phagemid heteroduplex with extracts of
HEK293 cells treated with EXO1 siRNA (see ‘Materials
and Methods’ section) yielded only background levels of
SalI-cleavable substrate (lane 2), similarly to the extract
supplemented with the recombinant EXO1 D173A mutant
(lane 5). Supplementation of the extract with recombinant
wild-type enzyme resulted in full restoration ofMMRactiv-
ity (lane 3), as did complementation with the EXO1 E109K
variant (lane 4). This result was anticipated from the data
obtained with the Exo1 E109K knock-in mouse, which was
deemed to have no MMR defect based on a phenotypic
comparison with the wild-type- and the knock-out animals
(28).
In the latter work, the E109K variant was assumed to
have no nuclease activity and it was therefore proposed that
EXO1 played a structural rather than a catalytic role in
MMR.This hypothesis was, however, incompatible with the
currently accepted mechanism of eukaryotic MMR (1,2),
which posits that mismatch-stimulated MutS/MutL re-
cruits and activates EXO1 to degrade the nicked strand up
to and past the mispaired nucleotide, generating thus a long
tract of single-stranded DNA that is subsequently filled-in
by DNA polymerase- (38). We, therefore, wished to verify
that the EXO1 E109K variant indeed lacked nuclease activ-
ity as reported by others (27,28). To this end, we incubated
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Figure 3. Wild-type EXO1 and its E109K variant complement the MMR
defect of EXO1-depleted extracts of HEK293 cells. (A) Schematic repre-
sentation of the T/G MMR substrate. The SalI restriction site contains
a T/G mismatch, which renders the site refractory to cleavage. Repair of
the T/G mismatch to C/G restores a bona fide SalI site. The SalI- and
the three DraI restriction sites are indicated. The restriction patterns seen
upon agarose gel electrophoresis before and after repair are shown on the
right. The Nt.BstNBI nicking site is located 316 nucleotides 5′ from the
mispaired T. (B) Mismatch repair assay using HEK293 siEXO1 extracts
supplemented with recombinant EXO1, either wild-type, or the E109K or
D173A variants. The reactions were stopped after 30 min and the recov-
ered substrates were digested with SalI/DraI. In the absence of repair, the
substrate gives rise to fragments of 2484, 694 and 19 bp, while the repaired
substrate generates fragments of 1324, 1160, 694 and 19 bp. The figure
shows a scan of a 1% agarose gel stained with GelRed. The image is repre-
sentative of three independent experiments.
the nicked phagemid substrate with the three recombinant
enzymes. No degradation was detectable upon incubation
of the substrate with the D173A variant, but addition of in-
creasing amounts of wild-type EXO1 or its E109K variant
resulted in substantial degradation of the nicked strands,
both enzymes yielding the single-stranded phagemid, which
is indicative of substantial processivity (Figure 4A). Similar
results were obtained in a time-course study at a constant
enzyme concentration (Figure 4B), as well as under varying
pH and salt concentrations (Supplementary Figure S2). In
all these experiments, the two enzymes behaved compara-
bly, even though the E109K mutant appeared to be repro-
ducibly slightly less efficient than the wild-type protein at
low enzyme concentrations. This result indicated that the
EXO1 E109K variant is not catalytically dead as previously
reported; rather, it possesses similar exonucleolytic activity
to the wild-type protein. This observation could be con-
firmed using a second substrate, an oligonucleotide duplex
with a 5′ recessed end (see ‘Materials andMethods’ section),
where removal of the 5′ 32P-labelled nucleotide took place
with similar kinetics upon incubation with the wild-type- or
the E109K-variant (Figure 4C).
We next decided to test whether the E109K mutation
might have affected the flap endonuclease activity of the en-
zyme (35), using a 50-mer oligonucleotide splayed-arm sub-
strate (see ‘Materials and Methods’ section) labelled with
32P on the unannealed 5′-terminus. As shown in Figure 5A,
incubation of this substrate with the wild-type enzyme re-
leased the labelled 19-mer flap, while theD173A variant was
Figure 4. Wild-type EXO1 and its E109K variant have comparable ex-
onucleolytic activities. (A) Exonucleolytic degradation of a nicked C/G
homoduplex substrate in the presence of the indicated concentrations of
the recombinant EXO1 variants for 10 min at 30◦C. Degradation of the
nicked strand gives rise to the faster-migrating single-stranded phagemid
DNA. (B) Time course of an exonucleolytic degradation of a nicked C/G
homoduplex substrate in the presence of 10 nM recombinant EXO1 vari-
ants. (C) Exonculeolytic degradation of a 5′- 32P labelled oligonucleotide
duplex with a recessed 5′ terminus in the presence of the indicated amounts
of EXO1 or its variants (0.1–10 nM) for 10 min at 30◦C. The substrate is
schematically shown on the right of the figure. The labelled strand is in-
dicated by a thicker line, with the 32P-labelled 5′ phosphate indicated by
a dot. Degradation liberates the rapidly migrating 5′ terminal nucleotide
(indicated by the dot on the right).
inactive in this assay. Interestingly, the EXO1 E109 variant
was slightly, but reproducibly, more active in this assay than
the wild-type enzyme. This could be explained by the pro-
posed role of the 4 helix in accommodating the 5′ flap (36),
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Figure 5. Endonucleolytic activities of wild-type EXO1 and its E109K
variant on a 50-mer splayed arm substrate. The substrate is schematically
shown on the left of the figure. The labelled strand is indicated by a thicker
line, with the 32P-labelled 5′ phosphate indicated by a dot. The substrate
(100 fmol) was incubated with 5 nM EXO1 variants for 3–30 min at 30◦C.
The reaction products were separated on 20% denaturing polyacrylamide
gels. EXO1-catalyzed cleavage liberates the 19-mer 32P-labelled 5′ flap. The
experiment was repeated four times and the figure shows an autoradio-
graph of a representative gel.
whereby the replacement of the acidic glutamate 109 for ly-
sine might stabilize this interaction.
DISCUSSION
Search for EXO1 mutations in LS/HNPCC identified 14
patients: one belonging to a typical HNPCC family who
carried a splice-site mutation in the gene and the others be-
longing to atypical LS families who carried missense mu-
tations that were not found in 200 control individuals and
were therefore judged to be disease-associated (4). However,
the causative nature of these mutations was uncertain; in
autosomal-dominant syndromes such as LS, tumourigen-
esis requires that the allele containing the germline muta-
tion be retained and the wild-type allele be silenced, mu-
tated or lost through loss of heterozygosity. Unexpectedly,
the wild-type allele was retained in all 13 analyzed tu-
mours, and a loss of the mutated allele was detected in 12
of these. In an attempt to define the role of EXO1 in tu-
mourigenesis, Edelmann et al. generated an Exo1 knock-
out mouse, which lacked exon 6 of the gene (23). As an-
ticipated, extracts of embryonal fibroblasts from these mice
lacked MMR activity, displayed elevated microsatellite in-
stability at a mononucleotide repeat marker and increased
mutation rates at the Hprt locus. The animals were suscep-
tible to lymphoma development, which implied that Exo1
is a tumour suppressor gene. That both genders were ster-
ile confirmed the role of Exo1 in meiosis, as shown earlier
in yeast (5,39,40). However, the very subtle predisposition
of these mice to tumourigenesis raised the possibility that
deletion of exon 6 may not have resulted in full inactivation
of the gene. The authors therefore generated an Exo1null/null
mouse, as well as a knock-in animal carrying the E109K
mutation (28), which was identified in an atypical LS fam-
ily (4). Phenotypic comparison of the wild-type-, E109K-
and null homozygous animals showed that the E109K mu-
tant resembled the wild-type in terms of fertility, mutation
frequency in the liver, spleen and small intestine, microsatel-
lite instability, somatic hypermutation, class switch recom-
bination and chromosomal stability or longevity in a p53-
deficient background. Based on the report that the E109K
mutant lacked nuclease activity (27), a finding also substan-
tiated by the authors (28), these similarities were interpreted
to mean that Exo1 plays an essential structural, rather than
an enzymatic, role in these processes (28). Our finding that
the EXO1 E109K mutant is fully enzymatically active as
an exo- and endonuclease contradicts this notion and ar-
gues that the above processes do indeed require the enzy-
matic function of EXO1, hence the phenotypic similarities
between the E109K knock-in and wild-type mice, and the
differences to the knock-out animals, which displayed de-
fects in the above functions. The reason underlying the lack
of enzymatic activity of the EXO1 E109K variant seen in
previous studies (27,28) might be linked to the presence of
the His6 tag at its N-terminus, or to the purification proto-
col, which involved denaturation of the polypeptide in urea
and refolding. Our protein was expressed with an intein tag,
but this was cleaved off during elution from the chitin beads.
Small differences in tumour spectra of the three mouse
models were reported, but the major differences were found
among the phenotypes of embryonal fibroblast cell lines es-
tablished from these mice. Thus, cells from the null- and
E109K mice were reported to be slightly more resistant to
MNNG, and displayed lowerDNAdamage response to this
chemical, which is normally indicative of a MMR defect.
This finding was unexpected, given that the knock-in an-
imals did not display an elevated mutation frequency and
that no MMR defect was seen in our in vitro experiments
(Figure 3).
The embryonal fibroblasts generated from the knock-in
mice displayed also somewhat greater chromosomal insta-
bility and sensitivity to camptothecin, a topoisomerase I in-
hibitor that stabilizes single strand breaks made by this en-
zyme. When such lesions reach replication forks, they are
converted to DSBs, which can cause cell cycle arrest and
trigger apoptosis. The repair of these breaks requires CtIP
and EXO1 for resection. We, therefore, wondered whether
the E109K mutant failed to interact with CtIP as reported
(37). As shown in Figure 2B, no difference between the vari-
ants was detected by far-western blotting. The above evi-
dence, coupledwith the finding that the biochemical param-
eters of the wild-type and the E109K variant proteins were
comparable, suggests that the phenotype of the embryonal
fibroblasts was not linked to the lack of a nuclease activity of
the E109K variant. One possible explanation concerns the
stability of the proteins in vivo. EXO1 is extensively post-
translationally modified and is highly-regulated by proteol-
ysis during the cell cycle and in response to DNA damage
(41). Given that the mutation at E109 generates a new ly-
sine residue, and thus a possible novel site for modifications
ranging from ubiquitylation and SUMOylation to methy-
lation and acetylation, the possibility that the mutation al-
ters the properties of the variant EXO1 enzyme and thus its
biological function in vivo should not be disregarded. Un-
fortunately, levels of the variant EXO1 proteins were not
described in these cell lines (28).
The data obtained in the course of this work show that
the biochemical properties of the EXO1 E109K variant are
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similar to that of the wild-type enzyme. Thus, in contrast to
Edelmann et al. (28), we conclude that the biological func-
tions of the enzyme require its nuclease activity. However, it
is possible that the E109K mutation alters the behaviour of
the protein in vivo, which clearly deserves further study.
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